Human trial
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Three-person pilot
Reported findings. Pigmentation in two
Nonresponse. One without reported pigmentation response
Harms. Nausea, fatigue/somnolence, spontaneous erections
Limits. No transfer to other routes/formulations/indications; clinician review pending.
Preparation: Melanotan II, not afamelanotide Route: subcutaneous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.